tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IMNM Stock Latest News

Immunome price target raised to $33 from $25 at Stephens
The FlyImmunome price target raised to $33 from $25 at Stephens
2d ago
IMNM
Immunome’s Strategic Clinical Advancements and Financial Alignment Justify Buy Rating
PremiumRatings
Immunome’s Strategic Clinical Advancements and Financial Alignment Justify Buy Rating
8d ago
IMNM
Immunome, Inc. Reports Q3 2025 Financial Results
PremiumCompany Announcements
Immunome, Inc. Reports Q3 2025 Financial Results
9d ago
IMNM
Immunome’s Strategic Advances and Promising Pipeline Justify Buy Rating
PremiumRatings
Immunome’s Strategic Advances and Promising Pipeline Justify Buy Rating
13d ago
IMNM
Immunome reports Q3 EPS (65c), consensus (54c)
PremiumThe Fly
Immunome reports Q3 EPS (65c), consensus (54c)
13d ago
IMNM
Immunome’s Phase 1 Cancer Study: A Potential Game-Changer?
PremiumCompany AnnouncementsImmunome’s Phase 1 Cancer Study: A Potential Game-Changer?
23d ago
IMNM
Immunome presents preclinical data on ADC payload HC74
Premium
The Fly
Immunome presents preclinical data on ADC payload HC74
27d ago
IMNM
Immunome’s Promising Pipeline and Management Confidence Drive Buy Rating
Premium
Ratings
Immunome’s Promising Pipeline and Management Confidence Drive Buy Rating
1M ago
IMNM
Immunome’s Promising Oncology Pipeline and Strong Market Potential Justify Buy Rating
PremiumRatings
Immunome’s Promising Oncology Pipeline and Strong Market Potential Justify Buy Rating
2M ago
IMNM
Immunome initiated with a Buy at Goldman Sachs
PremiumThe Fly
Immunome initiated with a Buy at Goldman Sachs
2M ago
IMNM
Immunome announces novel antibody collaboration with Infinimmune
PremiumThe Fly
Immunome announces novel antibody collaboration with Infinimmune
2M ago
IMNM
Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
PremiumThe Fly
Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
3M ago
IMNM
Immunome initiated with a Buy at Craig-Hallum
PremiumThe FlyImmunome initiated with a Buy at Craig-Hallum
3M ago
IMNM
Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
Premium
Ratings
Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
3M ago
IMNM
Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
Premium
The Fly
Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
3M ago
LI
DAY
Immunome initiated with an Outperform at Evercore ISI
PremiumThe Fly
Immunome initiated with an Outperform at Evercore ISI
3M ago
IMNM
Immunome’s Promising Pipeline and Financial Stability Justify Buy Rating
PremiumRatings
Immunome’s Promising Pipeline and Financial Stability Justify Buy Rating
3M ago
IMNM
Immunome Advances Cancer Therapy Pipeline Amid Financial Loss
PremiumCompany Announcements
Immunome Advances Cancer Therapy Pipeline Amid Financial Loss
3M ago
IMNM
Promising Outlook for Immunome’s Varegacestat: Buy Rating Affirmed
PremiumRatings
Promising Outlook for Immunome’s Varegacestat: Buy Rating Affirmed
3M ago
IMNM
Immunome’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
PremiumRatingsImmunome’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
3M ago
IMNM
Immunome reports Q2 EPS (50c), consensus (50c)
Premium
The Fly
Immunome reports Q2 EPS (50c), consensus (50c)
3M ago
IMNM
Immunome Elects New Directors at Annual Meeting
Premium
Company Announcements
Immunome Elects New Directors at Annual Meeting
5M ago
8K
IMNM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >